Assessing the arrhythmogenic propensity of fibrotic substrate using digital twins to inform a mechanisms-based atrial fibrillation ablation strategy.


Journal

Nature cardiovascular research
ISSN: 2731-0590
Titre abrégé: Nat Cardiovasc Res
Pays: England
ID NLM: 9918284280206676

Informations de publication

Date de publication:
Jul 2024
Historique:
medline: 19 8 2024
pubmed: 19 8 2024
entrez: 19 8 2024
Statut: ppublish

Résumé

Atrial fibrillation (AF), the most common heart rhythm disorder, may cause stroke and heart failure. For patients with persistent AF with fibrosis proliferation, the standard AF treatment-pulmonary vein isolation-has poor outcomes, necessitating redo procedures, owing to insufficient understanding of what constitutes good targets in fibrotic substrates. Here we present a prospective clinical and personalized digital twin study that characterizes the arrhythmogenic properties of persistent AF substrates and uncovers locations possessing rotor-attracting capabilities. Among these, a portion needs to be ablated to render the substrate not inducible for rotors, but the rest (37%) lose rotor-attracting capabilities when another location is ablated. Leveraging digital twin mechanistic insights, we suggest ablation targets that eliminate arrhythmia propensity with minimum lesions while also minimizing the risk of iatrogenic tachycardia and AF recurrence. Our findings provide further evidence regarding the appropriate substrate ablation targets in persistent AF, opening the door for effective strategies to mitigate patients' AF burden.

Identifiants

pubmed: 39157719
doi: 10.1038/s44161-024-00489-x
pmc: PMC11329066
doi:

Types de publication

Journal Article

Langues

eng

Pagination

857-868

Auteurs

Kensuke Sakata (K)

Alliance for Cardiovascular Diagnostic and Treatment Innovation, Johns Hopkins University, Baltimore, MD, USA.

Ryan P Bradley (RP)

Alliance for Cardiovascular Diagnostic and Treatment Innovation, Johns Hopkins University, Baltimore, MD, USA.
Research Computing, Lehigh University, Bethlehem, PA, USA.

Adityo Prakosa (A)

Alliance for Cardiovascular Diagnostic and Treatment Innovation, Johns Hopkins University, Baltimore, MD, USA.

Carolyna A P Yamamoto (CAP)

Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, USA.

Syed Yusuf Ali (SY)

Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, USA.

Shane Loeffler (S)

Alliance for Cardiovascular Diagnostic and Treatment Innovation, Johns Hopkins University, Baltimore, MD, USA.

Brock M Tice (BM)

Alliance for Cardiovascular Diagnostic and Treatment Innovation, Johns Hopkins University, Baltimore, MD, USA.

Patrick M Boyle (PM)

Center for Cardiovascular Biology, University of Washington, Seattle, WA, USA.
Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA, USA.

Eugene G Kholmovski (EG)

Alliance for Cardiovascular Diagnostic and Treatment Innovation, Johns Hopkins University, Baltimore, MD, USA.
Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, USA.

Ritu Yadav (R)

Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Sunil Kumar Sinha (SK)

Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Joseph E Marine (JE)

Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Hugh Calkins (H)

Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

David D Spragg (DD)

Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Natalia A Trayanova (NA)

Alliance for Cardiovascular Diagnostic and Treatment Innovation, Johns Hopkins University, Baltimore, MD, USA.
Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, USA.

Classifications MeSH